Abstract We reviewed 24 'real‐life'effectiveness studies of omalizumab in the treatment of
severe allergic asthma that included 4117 unique patients from 32 countries with significant …

Background After the approval of omalizumab for severe allergic asthma, a total of 25
studies have evaluated the effectiveness of omalizumab under “real-life” conditions of …

Background Assessment of clinical outcomes in the real-world corroborates findings from
randomized controlled trials (RCTs). Objective This meta-analysis evaluated real-world data …

Omalizumab has demonstrated therapeutic benefits in controlled clinical trials. Evaluation of
outcomes in real-world clinical practice is needed to provide a complete understanding of …

Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the
US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma …

Randomized clinical trials (RCTs) are the gold standard for the assessment of any
therapeutic intervention. Real-life (RL) studies are needed to verify the provided results …

Omalizumab (Xolair®) is a subcutaneously administered monoclonal antibody that targets
circulating free IgE and prevents its interaction with the high-affinity IgE receptor (FCεRI) …

Objectives: The aim of this study was to assess the stability of the effectiveness of
omalizumab as add-on treatment in 11 patients with severe persistent allergic asthma …

Omalizumab has been shown to be an effective add-on therapy for patients with
uncontrolled severe persistent allergic asthma. There has been a steady accumulation of …

BACKGROUND: Omalizumab is a monoclonal antibody indicated for treatment of severe
persistent allergic asthma inadequately controlled despite optimal controller therapy. We …